Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Myelodysplastic syndromes (MDS)

ASCO Direct Highlights™ Miami 2021 Symposium

9 - 10 Jul 2021

Published: 6 Aug 2021

Views: 532

Rating:

Save

Dr Fernando Vargas - Memorial Healthcare System, FL, USA

Dr Fernando Vargas speaks to ecancer about myelodysplastic syndromes (MDS) at the ASCO Direct Highlights Miami Symposium 2021. Dr Vargas gives detailed updates on some of the most recent MDS trials including those presented at ASCO 2021.

Related Videos

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients

Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients ( Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA )

Daratumumab and lenalidomide for frail patients with newly diagnosed multiple myeloma shows promising survival results

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Daratumumab and lenalidomide for frail patients with newly diagnosed multiple myeloma shows promising survival results ( Prof Salomon Manier - Hospital Center University De Lille, Lille, France )

30 minute infusion of isatuximab shows potential in newly diagnosed multiple myeloma

Prof Philippe Moreau - University Hospital of Nantes, Nantes, France

30 minute infusion of isatuximab shows potential in newly diagnosed multiple myeloma ( Prof Philippe Moreau - University Hospital of Nantes, Nantes, France )

Understanding the remaining unmet needs in a post ASCT NDMM setting

Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway

Understanding the remaining unmet needs in a post ASCT NDMM setting ( Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway )

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients ( Prof Salomon Manier - Hospital Center University De Lille, Lille, France )

Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM

Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece

Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM ( Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece )

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma

Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France

ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma ( Prof Xavier Leleu - Poitiers Centre Hospitalier Universitaire, Poitiers, France )

Epitope editing enables targeted immunotherapy of acute myeloid leukaemia

Dr Gabriele Casirati - Dana-Farber Cancer Institute, Boston, USA

Epitope editing enables targeted immunotherapy of acute myeloid leukaemia ( Dr Gabriele Casirati - Dana-Farber Cancer Institute, Boston, USA )

Hodgkin’s and non-Hodgkin’s lymphomas (NHL)

Dr Jose Sandoval Sus - Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System, Florida, USA

Hodgkin’s and non-Hodgkin’s lymphomas (NHL) ( Dr Jose Sandoval Sus - Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System, Florida, USA )

More from ecancer